What happened with the FDA and compounded GLP-1s, and who is still operating legally?

The situation with the FDA and compounded GLP-1s (like semaglutide and tirzepatide) is complex and has been a significant point of contention. Here's a breakdown of what happened and who is still operating legally from the FDA's perspective:

What Happened with the FDA and Compounded GLP-1s?

1. High Demand & Shortages: The immense popularity of FDA-approved GLP-1 medications like Ozempic, Wegovy (semaglutide), Mounjaro, and Zepbound (tirzepatide) for weight loss and diabetes management led to widespread shortages.

2. Rise of Compounding: During these shortages, many compounding pharmacies and telehealth companies began offering "compounded" versions of these drugs. Compounding is the practice of mixing or altering ingredients to create a medication tailored to an individual patient, typically when the FDA-approved version isn't available or suitable.

3. FDA's Concerns & Warnings: The FDA quickly became concerned about these compounded versions for several reasons:

   • Unapproved Ingredients: Many compounded semaglutide products were using semaglutide sodium or semaglutide acetate, which are different salt forms from the active ingredient in FDA-approved semaglutide products (semaglutide base). The FDA has stated that these salt forms are not approved for compounding.
   • Lack of Quality Control: Compounded drugs are not subject to the same rigorous FDA review for safety, efficacy, and quality as commercially manufactured drugs. The FDA warned about potential issues with sterility, purity, potency, and the risk of adverse events.
   • Misleading Marketing: Some companies were deceptively marketing their compounded products as "FDA-approved" or equivalent to the brand-name versions.
   • "Copycats" vs. Legitimate Compounding: The FDA's stance is that compounding should only occur when there's an active shortage of an FDA-approved drug and the compounded version uses an active pharmaceutical ingredient (API) that is specifically on the FDA's "bulk drug substances list" or meets other specific criteria. For tirzepatide, there is no FDA-approved API for compounding, making any compounded tirzepatide problematic from the FDA's viewpoint.
   • Specific Actions: The FDA issued numerous warning letters to compounding pharmacies and telehealth platforms that were selling unapproved compounded GLP-1s, particularly those using semaglutide sodium or selling compounded tirzepatide. They also released consumer alerts.

4. Ongoing Stance: The FDA continues to strongly advise against using compounded semaglutide or tirzepatide due to safety and quality concerns, especially if they use unapproved salt forms or are offered outside of legitimate compounding parameters during a shortage.

Who Is Still Operating Legally (According to FDA Guidance)?

When discussing "legally," it's crucial to distinguish between FDA-approved medications and compounded versions, and then within compounding, distinguish between what the FDA permits versus what it warns against.

1. The Gold Standard: FDA-Approved Brand Name Medications This is the safest and most recommended option, fully reviewed and regulated by the FDA.

• Brands:
  • For Type 2 Diabetes & Weight Loss: Ozempic (semaglutide) and Mounjaro (tirzepatide).
  • For Weight Loss Only: Wegovy (semaglutide) and Zepbound (tirzepatide).
• How to get them: Requires a prescription from a licensed healthcare provider (doctor, nurse practitioner, physician assistant) and is filled at a traditional, state-licensed retail pharmacy (e.g., CVS Pharmacy, Walgreens, Rite Aid, Kroger Pharmacy, local independent pharmacies).
• Why it's legal: These drugs have undergone rigorous clinical trials and FDA approval processes for safety, efficacy, and quality.

2. Compounded Medications (With Significant Caveats and FDA Warnings)

For compounding to be considered "legal" by the FDA for GLP-1s, it must adhere to very strict conditions:

• Active FDA Shortage: Compounding is generally only permitted during an active FDA-reported shortage of the commercially available, FDA-approved drug.
• Patient-Specific Prescription: The medication must be compounded for an individual patient based on a valid prescription from a licensed healthcare provider.
• Approved Active Pharmaceutical Ingredient (API):
  • For semaglutide: The FDA has stated that only semaglutide base (the same API as in the approved drugs) is acceptable for compounding, and only during a shortage. Using semaglutide sodium or other salt forms for compounding is considered illegal by the FDA.
  • For tirzepatide: There is no FDA-approved API for compounding tirzepatide. Therefore, any compounded tirzepatide product is considered unapproved by the FDA.
• Licensed Pharmacies:
  • 503A Compounding Pharmacies: These are traditional, state-licensed retail pharmacies that compound medications for individual patients based on a prescription. They are regulated by state boards of pharmacy. They must follow the above rules regarding APIs and shortages.
  • 503B Outsourcing Facilities: These are facilities that compound sterile medications in larger batches for hospitals and clinics. They are subject to more stringent FDA oversight (like manufacturing facilities). They also must adhere to the same API and shortage rules.

To identify a potentially "legal" compounded GLP-1 (specifically semaglutide, as tirzepatide is a no-go from the FDA's perspective):

• You MUST have a valid, in-person or synchronous telehealth consultation and prescription from a licensed healthcare provider.
• The pharmacy must be state-licensed and ideally be transparent about their sourcing and testing.
• The pharmacy explicitly states they are compounding semaglutide base (not semaglutide sodium or other salts).
• They are operating only because there is an active FDA shortage of the brand-name drug.

Warning Signs of Illegality (or operating against FDA guidance):

• Any provider or pharmacy offering "compounded tirzepatide."
• Any provider or pharmacy offering compounded semaglutide sodium or other non-base forms.
• Companies offering "generic" versions of these drugs (there are no generic versions available yet).
• Online clinics that promise extremely low prices without a proper consultation or that push compounded versions excessively.
• Pharmacies that claim their compounded GLP-1s are "FDA-approved" or equivalent to the brand-name drugs.

Recommendation: If you are considering GLP-1 medications, always prioritize the FDA-approved brand-name drugs (Ozempic, Wegovy, Mounjaro, Zepbound) with a prescription from your doctor and filled at a reputable pharmacy. If you explore compounded options, be extremely cautious, verify all credentials, and ensure the pharmacy adheres strictly to FDA guidelines regarding ingredients and shortages.